Yatharth Hospital
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Yatharth Hospital's recent strategic initiatives, particularly its partnership with Advent International, are pivotal in enhancing its acquisition capabilities and operational efficiencies. Management's focus on expanding bed capacity to 5,000 over the next three years, alongside a robust pipeline of acquisitions, positions the company for sustained revenue growth despite current margin pressures. The anticipated organic growth trajectory of over 30% reflects strong demand for super-specialty care in urban markets, although execution risks and regulatory challenges remain pertinent. Vista's financial outlook aligns with these developments, projecting moderate revenue growth and stable margins, supported by a fair valuation and an expected upside of approximately 4.28%. The healthcare sector's structural tailwinds, including increasing demand and government initiatives, bolster Yatharth's growth potential, although competitive pricing pressures and rising operational costs could pose challenges. Over the next 12-24 months, key opportunities include successful integration of new assets and expansion into high-value specialties, while watchpoints include execution risks and potential regulatory impacts on pricing strategies
Why We Like This Stock
- Strategic partnership with Advent International enhances acquisition capabilities and operational efficiencies
- Management's aggressive expansion plan aims to increase bed capacity to 5,000, targeting high-demand urban markets
- Strong organic growth trajectory of over 30% supported by favorable market conditions and government initiatives
Things To Watch Out For
- Execution risks related to rapid capacity expansion and integration of new assets could impact performance
- Competitive pricing pressures and rising operational costs may constrain margins
- Regulatory challenges in the healthcare sector could affect operational flexibility and pricing strategies
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 635 | 860 | 1,207 | 1,375 | 1,763 |
| Profit Before Tax (Cr.) | 157 | 170 | 224 | 236 | 296 |
| PBT Margin | 24.7% | 19.8% | 18.6% | 17.1% | 16.8% |
| Net Profit (Cr.) | 116 | 122 | 170 | 179 | 218 |
| Earnings Per Share | 12.0 | 12.7 | 18.2 | 18.0 | 22.7 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Choice Equity | ▲ Buy | 1,350 | 30-Sep-2026 |
| Nuvama | ▲ Buy | 950 | 27-May-2026 |
Company Overview
Show Company Profile
Yatharth Hospital & Trauma Care Services Limited, together with its subsidiaries, owns and operates super-specialty hospitals in India. The company offers services in the areas of medicine, cardiology, neurosciences, general surgery, nephrology and urology, pediatrics, gastroenterology, pulmonology, gynecology, orthopedics, spine and rheumatology, plastic and cosmetic surgery, ear, nose, throat, endocrinology, critical care, dermatology, nuclear medicine, and cancer and bone marrow transplant. It also provides services in the areas of GI surgery and liver transplant, robotic surgery, kidney transplant, IVF and fertility, emergency medicine, ophthalmology, dentistry, psychology and psychiatry, physiotherapy and rehabilitation, anesthesiology, radiology, pathology and laboratory medicine, nutrition and health, interventional spine and pain medicine, neurology, neurosurgery, and cardiovascular and thoracic surgery. In addition, the company sells medicines and canteen food. The company was incorporated in 2008 and is based in Noida, India.